Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

35.300
+1.7805.31%
Volume:13.13M
Turnover:457.36M
Market Cap:214.06B
PE:32.49
High:35.420
Open:33.200
Low:33.200
Close:33.520
52wk High:43.587
52wk Low:27.658
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:2.05
T/O Rate:0.22%
Dividend:0.49
Dividend Rate:1.40%
EPS(LYR):1.087
ROE:19.40%
ROA:9.08%
PB:4.85
PE(LYR):32.49
PS:11.52

Loading ...

Movement Alert|HANSOH PHARMA Rises 3.12% in Regular Trading, B7-H3 ADC Phase III Data Reveals Record-Breaking Survival Benefit in Small Cell Lung Cancer

Market Focus
·
Sep 14

Hansoh Pharma Says Phase 3 Artemis-008 Study Shows Overall Survival Gain for Risvutatug Rezetecan in Relapsed SCLC

Reuters
·
Sep 13

Hansoh Pharmaceutical Says Risvutatug Rezetecan Injection Included in NMPA Priority Review

Reuters
·
Sep 11

Hansoh Pharma’s Risvutatug Rezetecan for Small-Cell Lung Cancer Enters NMPA Priority Review

Bulletin Express
·
Sep 11

Hansoh Pharma's Investigational Therapy for Small Cell Lung Cancer Granted Priority Review by Chinese Regulator

Stock News
·
Sep 11

Hansoh Pharmaceutical Group Stock Slides 1.9% in Hong Kong

Dow Jones
·
Sep 11

Hansoh Pharma Says NMPA Grants Priority Review for HS-20093 in Small Cell Lung Cancer

Reuters
·
Sep 11

Hansoh Pharmaceutical - Risvutatug Rezetecan for Injection Included in Nmpa Priority Review for Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 11

Movement Alert|HANSOH PHARMA Falls 3.06% in Regular Trading, Post-Earnings Rally Continues to Retrace Amid Sector Weakness

Market Focus
·
Sep 11

Hansoh Pharmaceutical Group Stock Falls 4.2% in Hong Kong

Dow Jones
·
Sep 10

Movement Alert|HANSOH PHARMA Falls 3.22% in Regular Trading, Pharmaceutical Sector Under Broad Pressure as Post-Earnings Rally Continues to Retrace

Market Focus
·
Sep 10

Hansoh Pharmaceutical Group Stock Falls 3.5% in Hong Kong

Dow Jones
·
Sep 09

UBS: Mixed First-Half Results for Chinese Pharma Stocks, Names Simcere as Top Pick

Stock News
·
Sep 09

Movement Alert|HANSOH PHARMA Falls 3.1% in Regular Trading, Broad Pharma Sector Selloff Drags Down Stock

Market Focus
·
Sep 09

CLSA Highlights Return of Stock-Specific Drivers in China's Innovative Drug Sector, Sees Macro Swings as Entry Points

Stock News
·
Sep 09

Hansoh Pharma Says China NMPA Accepts BLA for HS-20093 in Small Cell Lung Cancer

Reuters
·
Sep 07

One-Day Surge, Three-Day Slump: Can Hansoh Pharma's Shares Climb Back to HK$40?

Stock News
·
Sep 02

HANSOH PHARMA's Investigational ADC for Small Cell Lung Cancer Wins NMPA Filing Acceptance

Stock News
·
Sep 02

Hansoh Pharma Says China NMPA Accepts HS-20093 BLA for Small Cell Lung Cancer

Reuters
·
Sep 02

Hansoh Pharmaceutical Group Stock Climbs 2.2% in Hong Kong

Dow Jones
·
Sep 02